Cebaracetam

From Wikipedia the free encyclopedia

Cebaracetam
Clinical data
Other namesCGS-25248; ZY-15119
ATC code
  • None
Legal status
Legal status
  • US: Unscheduled and not FDA approved
Identifiers
  • 4-[2-[4-(4-Chlorophenyl)-2-oxopyrrolidin-1-yl]acetyl]piperazin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H18ClN3O3
Molar mass335.79 g·mol−1
3D model (JSmol)
  • C1CN(CC(=O)N1)C(=O)CN2CC(CC2=O)C3=CC=C(C=C3)Cl
  • InChI=1S/C16H18ClN3O3/c17-13-3-1-11(2-4-13)12-7-15(22)20(8-12)10-16(23)19-6-5-18-14(21)9-19/h1-4,12H,5-10H2,(H,18,21) ☒N
  • Key:QPKMIYNBZGPJAR-UHFFFAOYSA-N ☒N
  (verify)

Cebaracetam (INNTooltip International Nonproprietary Name; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed.[1][2][3]

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam).[4] It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety.[4] The mechanism of action of cebaracetam is undefined or unknown.[1]

The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995.[1] It reached phase 2 clinical trials prior to its discontinuation.[1]

References

[edit]
  1. ^ a b c d "Cebaracetam". AdisInsight. 23 May 1995. Retrieved 1 October 2024.
  2. ^ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/stembook-2018.pdf
  3. ^ Chollet D, Künstner P (June 1992). "Fast systematic approach for the determination of drugs in biological fluids by fully automated high-performance liquid chromatography with on-line solid-phase extraction and automated cartridge exchange. Application to cebaracetam in human urine". Journal of Chromatography. 577 (2): 335–340. doi:10.1016/0378-4347(92)80255-o. PMID 1400764.
  4. ^ a b "Cebaracetam". PubChem. Retrieved 1 October 2024.